{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:36:35Z","timestamp":1769074595654,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hyperuricemia is a state in which the serum levels of uric acid (UA) are elevated. This study was to determine the roles of rosuvastatin in fasting blood glucose (FGB) and insulin levels in hyperuricemic rats.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty-six Sprague-Dawley (SD) rats were randomized divided into the control, model and rosuvastatin groups: the control was given no intervention, the model group was established by administrating yeast extract powder and oxonic acid potassium salt, and the rosuvastatin group was given intravenous administration of rosuvastatin for 28\u2009days in hyperuricemic rats. Serum uric acid (SUA), fasting blood glucose (FBG), fasting blood insulin (FBI), glutamic acid decarboxylase antibody (GADA), oral glucose tolerance test (OGTT) levels, and the ultrastructure of pancreatic \u03b2-cells were measured. Also, homeostasis model assessment of insulin resistance (HOMA-IR) scores was computed in three groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared to the model group, SUA were decreased, while the FBG, GADA, OGTT and HOMA-IR at week 4 were significantly increased in rosuvastatin group. However, FBI was not significantly changed between three groups. It was also showed that the structure of pancreatic \u03b2-cells was damaged and the number of \u03b2-cells was changed in hyperuricemic rats while they were aggravated in rosuvastatin group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Rosuvastatin has roles in inducing FGB, GADA, OGTT and pancreatic \u03b2-cells damage in hyperuricemic rats.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-022-00595-1","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T11:03:08Z","timestamp":1662375788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats"],"prefix":"10.1186","volume":"23","author":[{"given":"Dilidaer","family":"Xilifu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zumulaiti","family":"Tuerxun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buweiayixiemu","family":"Nuermaimaiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayinu","family":"Aili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nijiati","family":"Rehemu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"595_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","volume":"80","author":"C Borghi","year":"2020","unstructured":"Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1\u201311.","journal-title":"Eur J Intern Med"},{"key":"595_CR2","doi-asserted-by":"publisher","first-page":"f2610","DOI":"10.1136\/bmj.f2610","volume":"346","author":"AA Carter","year":"2013","unstructured":"Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.","journal-title":"BMJ."},{"key":"595_CR3","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshahai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556\u201364.","journal-title":"JAMA."},{"issue":"10","key":"595_CR4","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1253\/circj.CJ-14-0810","volume":"78","author":"H Ogawa","year":"2014","unstructured":"Ogawa H, Matsui K, Saito Y, Sugiyama S, Jinnouchi H, Sugawara M, et al. Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study. Circ J. 2014;78(10):2512\u20135.","journal-title":"Circ J"},{"issue":"1","key":"595_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5799\/ahinjs.01.2016.01.0561","volume":"7","author":"N Basaran","year":"2016","unstructured":"Basaran N, Evliyaoglu O, Sucu V, Dikker O, Bulut L, Tezcan F, et al. Changing of uric acid levels by age and sex in patients with diabetes mellitus. J Clin Exp Invest. 2016;7(1):1\u20136.","journal-title":"J Clin Exp Invest"},{"issue":"2","key":"595_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/BOR.0b013e32835d951e","volume":"25","author":"C Li","year":"2013","unstructured":"Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210\u20136.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"595_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2337\/db19-0178","volume":"69","author":"LY Shen","year":"2020","unstructured":"Shen LY, Gu YY, Qiu YX. Atorvastatin targets the islet mevalonate pathway to dysregulate mTOR signaling and reduce \u03b2-cell functional mass. Diabetes. 2020;69(1):48\u201359.","journal-title":"Diabetes."},{"key":"595_CR8","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.2337\/db12-1814","volume":"62","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, et al. Sugar, uric acid, and etiology of diabetes and obesity. Diabetes. 2013;62:3307\u201315.","journal-title":"Diabetes."},{"key":"595_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735\u201342.","journal-title":"Lancet."},{"key":"595_CR10","doi-asserted-by":"publisher","first-page":"g3244","DOI":"10.1136\/bmj.g3244","volume":"348","author":"CR Dormuth","year":"2014","unstructured":"Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244.","journal-title":"BMJ."},{"key":"595_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565\u201371.","journal-title":"Lancet."},{"key":"595_CR12","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3892\/etm.2014.2027","volume":"8","author":"D Xilifu","year":"2014","unstructured":"Xilifu D, Abulizi A, Rehemu N, Zhao L, Zhou X, Zhang XY. Effect of rosuvastatin on hyperuricemic rats and the protective effect on endothelial dysfunction. Exp Ther Med. 2014;8:1683\u20138.","journal-title":"Exp Ther Med"},{"key":"595_CR13","unstructured":"Dilidaer XLF, Zhao P, Song LJ, Rehemu N, Zhang XY. Development of secondary cardiovascular disease in hyper- uricemia model rats induced by yeast extract combined with oteracil. Chin J Tissue Engineer Res. 2011;16(11):231\u20134."},{"key":"595_CR14","unstructured":"Guide For The Care And Use Of Laboratory Animals 8th Edition. Washington, D. C: The National Academies Press;\u00a02011.\u00a0p. 11\u201335."},{"issue":"2","key":"595_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1476-5381.2009.00548.x","volume":"159","author":"M Otani","year":"2010","unstructured":"Otani M, Yamamoto M, Harada M, Otsuki M. Effect of long- and short-term treatments with pravastatin on diabetes mellitus and pancreatic fibrosis in the Otsuka-long-Evans-Tokushima fatty rat. Br J Pharmacol. 2010;159(2):462\u201373.","journal-title":"Br J Pharmacol"},{"key":"595_CR16","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/ajh.2011.55","volume":"24","author":"H Tomiyama","year":"2011","unstructured":"Tomiyama H, Higashi Y, Takase B, Node K, Sata M, Inoue T, et al. Relationships among metabolic syndrome, and endothelial function. Am J Hypertens. 2011;24:770\u20134.","journal-title":"Am J Hypertens"},{"key":"595_CR17","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/ptr.3421","volume":"25","author":"KS Hwa","year":"2011","unstructured":"Hwa KS, Chung DM, Chung YC, Chun HK. Hypouricemic effects of anthocyanin extracts of purple sweet potato on potassium oxonate-induced hyperuricemia in mice. Phytother Res. 2011;25:1415\u20137.","journal-title":"Phytother Res"},{"issue":"2","key":"595_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5455\/ijmsph.2015.0310201435","volume":"4","author":"CR Acharya","year":"2015","unstructured":"Acharya CR, Sharma AK, Kantaria ND. Involvement of oxidative stress in patients of gout and antioxidant effect of allopurinol. Int J Med Sci Public Health. 2015;4(2):168\u201372.","journal-title":"Int J Med Sci Public Health"},{"key":"595_CR19","doi-asserted-by":"publisher","first-page":"193095","DOI":"10.1155\/2014\/193095","volume":"2014","author":"A Magenta","year":"2014","unstructured":"Magenta A, Greco S, Capogrossi MC, Gaetano C, Martelli F. Nitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunction. Biomed Res Int. 2014;2014:193095.","journal-title":"Biomed Res Int"},{"key":"595_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.mam.2004.02.019","volume":"25","author":"OR Koch","year":"2004","unstructured":"Koch OR, Pani G, Borrello S, Colavitti R, Cravero A, Farre S, et al. Oxidative stress and antioxidant defenses in ethanol-induced cell injury. Mol Asp Med. 2004;25:191\u20138.","journal-title":"Mol Asp Med"},{"issue":"1","key":"595_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00006676-200101000-00009","volume":"22","author":"N Matsumura","year":"2001","unstructured":"Matsumura N, Ochi K, Ichimura M, Mizushima T, Harada H, Harada M. Study on free radicals and pancreatic fibrosis--pancreatic fibrosis induced by repeated injections of superoxide dismutase inhibitor. Pancreas. 2001;22(1):53\u20137.","journal-title":"Pancreas."},{"key":"595_CR22","doi-asserted-by":"publisher","first-page":"582680","DOI":"10.3389\/fphar.2020.582680","volume":"11","author":"Y Wei","year":"2020","unstructured":"Wei Y, Cheng JD. Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol. 2020;11:582680.","journal-title":"Front Pharmacol"},{"issue":"4","key":"595_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s13340-017-0328-9","volume":"8","author":"A Kameda","year":"2017","unstructured":"Kameda A, Nakamura A, Kondo Y. Effects of switching to low-dose rosuvastatin (5 mg\/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trial. Diabetol Int. 2017;8(4):383\u201391.","journal-title":"Diabetol Int"},{"key":"595_CR24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/j.1742-1241.2011.02779.x","volume":"65","author":"E Moutzouri","year":"2011","unstructured":"Moutzouri E, Liberopoulos E, Mikhailidis D, Kostapanos M, Kei A, Milionis H, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin\/ezetimibe on parameters of insulin resistance. Int J Clin Pract. 2011;65:1141\u20138.","journal-title":"Int J Clin Pract"},{"issue":"25","key":"595_CR25","doi-asserted-by":"publisher","first-page":"11416","DOI":"10.7150\/thno.49770","volume":"10","author":"MY Shi","year":"2020","unstructured":"Shi MY, Bang IH, Chang Han CY. Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis. Theranostics. 2020;10(25):11416\u201327.","journal-title":"Theranostics."},{"key":"595_CR26","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEJM. 2008;359:2195\u2013207.","journal-title":"NEJM."},{"key":"595_CR27","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1210\/jc.2018-01446","volume":"103","author":"LR Braun","year":"2018","unstructured":"Braun LR, Feldpausch MN, Czerwonka N, Weiss J, Branch K, Lee H, et al. Effects of pitavastatin on insulin sensitivity and liver fat: a randomized clinical trial. J Clin Endocrinol Metab. 2018;103:4176\u201386.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"595_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12933-018-0799-4","volume":"17","author":"JK Kim","year":"2018","unstructured":"Kim JK, Lee HS, Lee KY. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovasc Diabetol. 2018;17(1):155.","journal-title":"Cardiovasc Diabetol"},{"key":"595_CR29","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41:S13\u201327.","journal-title":"Diabetes Care"},{"key":"595_CR30","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2337\/dc12-0931","volume":"36","author":"MI Hawa","year":"2013","unstructured":"Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care. 2013;36:908\u201313.","journal-title":"Diabetes Care"},{"issue":"6","key":"595_CR31","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/jdi.13052","volume":"10","author":"S Yamamura","year":"2019","unstructured":"Yamamura S, Fukui T, Mori Y, Hayashi T, Yamamoto T, Ohara M, et al. Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population. J Diabetes Investig. 2019;10(6):1480\u20139.","journal-title":"J Diabetes Investig"},{"issue":"8","key":"595_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/pedi.12346","volume":"17","author":"E Ganelin-Cohen","year":"2016","unstructured":"Ganelin-Cohen E, Modan-Moses D, Hemi R, Kanety H, Ben-Zeev B, Hampe CS. Epilepsy and behavioral changes, type 1 diabetes mellitus and a high titer of glutamic acid decarboxylase antibodies. Pediatr Diabetes. 2016;17(8):617\u201322.","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"595_CR33","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/HCO.0b013e3283470359","volume":"26","author":"UK Sampson","year":"2011","unstructured":"Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26(4):342\u20137.","journal-title":"Curr Opin Cardiol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-022-00595-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T12:36:41Z","timestamp":1664973401000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-022-00595-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1186\/s40360-022-00595-1","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was strictly performed in accordance with the Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Ethical Committee of the First Affiliated Hospital of Xinjiang Medical University (No. 20100310003). The study is reported in accordance with ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}